CellCyte Genetics Corp. Forms Device Division to Develop and
Manufacture Stem Cell Cultivation and Replication Products
September 19, 2007: 09:15 AM EST
KIRKLAND, Wash., Sept. 19 /PRNewswire-
Corporation (the "Company") has formed a new Device Division in order
to develop, manufacture and market its patented line of stem cell
cultivation and replication devices.
CellCyte Genetics is developing stem cell enabling therapeutic
products designed to allow more efficient delivery and significantly
increased retention of adult stem cells to diseased organs, such as
the heart.
Along with its planned human trials for its therapeutics, CellCyte
Genetics intends to develop a new stem cell cultivation device
or "bioreactor" unit for which CellCyte Genetics owns the worldwide
patent and rights. The Company plans to market the device for
applications that will require cells to be grown under regulated
oxygen concentrations, e.g. the replication of stem cells and the
culture of pancreatic islet cells prior to transplantation into
diabetic patients.
Dr. Ron Berninger, Chief Scientific Officer of CellCyte Genetics
explains, "CellCyte's patented biological cell maintenance system has
the unique ability to incubate cultured cells with a very efficient
and regulatable oxygen supply, making it an ideal choice for
culturing cells that are otherwise difficult to keep alive or to
expand. Inside the bioreactor, the cells can also form a 3-
dimensional network, which is what most cell types do in major organs
of the body."
A key element of this bioreactor is the capability to supply oxygen
(by bundles of oxygen fibers) to the cells throughout the entire
space in which cells are growing. Stem cells appear to be sensitive
to oxygen levels and can be induced to replicate or differentiate in
part by controlling the oxygen level.
Using CellCyte's product, scientists, researchers and clinicians
should be able to dramatically increase the number of stem cells
available for research and potentially for use in stem cell
therapies. Management believes that the bioreactor unit will be the
Company's first revenue producing research product and is expected be
ready for market in 2008.
CellCyte Genetics acquired the patents and rights to the bioreactor
unit and several other key technologies from the developer of the
technology in 2006 as part of its original Intellectual property
portfolio. The Company began work on remolding key parts of the
bioreactor for manufacturing earlier this year as part of CellCyte's
efforts to prepare for human trials and FDA application for the use
of its stem cell therapies. With the manufacturing path and contract
suppliers now set, CellCyte has begun gearing up this Device Division
to complete development of the bioreactor and several other
synergistic technologies.
The Device Division will operate as a separate division of the
Company and will carry out R & D, manufacturing, and sales and
marketing functions through the facilities of CellCyte Genetics' new
facilities in Bothell near Seattle, Washington.
About CellCyte Genetics
CellCyte Genetics, a Washington State company, is an emerging
biotechnology company engaged in the principle business of the
discovery, development and commercialization of breakthrough stem
cell enabling therapeutic products.
For further information see: http://www.cellcyte
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
